QuantifiCare partners with LBO France to accelerate its global expansion.
LBO France invests €5m through its new Digital Health 2 venture fund.
3 September 2019
Sophia Antipolis, France – QuantifiCare, a global leader in 3D imaging solutions for clinical trials and aesthetic specialists, announces it raised €5m from LBO France to accelerate its expansion plans and strengthen its prominent position in skin imaging worldwide. QuantifiCare is the first investment of Digital Health 2, the new venture fund of LBO France.
Founded in 2001 as a spin-off of INRIA, QuantifiCare is an imaging Contract Research Organization (CRO) specializing in skin evaluations for clinical trials to pharmaceutical and cosmetic companies in major indications such as dermatology, aesthetics, wound healing and oncology. Building upon state-of-the-art, patented technology, QuantifiCare also offers a full range of high-quality 3D cameras and software applications which are revolutionizing the way plastic surgeons, dermatologists and aesthetic specialists are visualizing pre and post-surgery, making treatment recommendations and ultimately improving communication with their patients.
QuantifiCare’s solutions have been deployed in several thousand clinical sites across sixty countries. The investment will allow the group to reinforce its leading position with top pharmaceutical sponsors and aesthetic practitioners, and further develop its existing operations in the United States, Latin America, the Middle East and Asia.
Jean-Philippe Thirion, Founder & CEO of QuantifiCare, explains: “We are thrilled to have LBO France, a leading investor in digital health, backing QuantifiCare and joining our board to help us execute our global strategy. We already offer the most advanced 3D solutions for medical and clinical use. The funds raised will enable us to intensify our marketing, R&D and operations internationally, accelerate our growth and strengthen our leadership position in 2D/3D skin imaging worldwide.”
Franck Noiret, Managing Director at LBO France, adds: “QuantifiCare is a great example of the emerging power of digital technologies to finally provide objective data to medical practitioners, allowing them to better plan and validate their interventions and communicate with patients. We are delighted to partner with QuantifiCare as the first investment of Digital Health 2. QuantifiCare is revolutionizing pre and post-surgery skin visualization for both the physician and the patient, making 3D imaging a “must have” for any aesthetic procedure. Given its established positions in clinical studies and as a provider of 3D solutions to aesthetics specialists worldwide, we are confident it will continue to grow fast and innovate to improve care standards.”
QuantifiCare, a spin-off of INRIA, is a global leader in 2D/3D imaging systems and services helping Sponsors and CROs to bring quality and simplicity to the evaluation of images for clinical trials in dermatology, aesthetics, wound care and oncology. Founded in 2001, QuantifiCare has built on its clinical experience and expanded to provide a full range of innovative 3D imaging systems for dermatologists and plastic surgeons to visualize pre-post treatments, measure and simulate surgical interventions and better communicate with their patients. QuantifiCare has conducted hundreds of clinical trials and the patented award winning 3D LifeViz® systems are used in over sixty countries. The company is expanding its patented technologies and services to include AI and Cloud applications. With headquarter offices in France and operations in the USA, Latin America and Asia, QuantifiCare is poised for tremendous growth in the future.
Find out more: www.quantificare.com
Contacts: Jean-Philippe Thirion, Founder & CEO / Aurore Baud, Marketing Manager
firstname.lastname@example.org / +33 4 92 91 54 20
About INRIA: www.inria.fr
About LBO France
As a key player in private equity with €4bn of capital under management, LBO France is an independent company that has been supporting European companies in their growth for more than 30 years. Its investment strategy is built on 4 distinct segments managed by dedicated teams: (i) Mid Cap Buyout through the White Knight funds and Small Cap Buyout through the Hexagone/Small Caps Opportunities funds, (ii) Venture Capital through the SISA/Digital Health funds, (iii) Real Estate through the White Stone and Lapillus funds, (iv) Debt. LBO France is 100% owned by its management and employs nearly 60 professionals.
Find out more: www.lbofrance.com
Contact: Franck Noiret, Managing Director
email@example.com / +33 6 72 81 35 17
Lola Gozlan – firstname.lastname@example.org / +33 1 44 50 58 72
Léa Schultz – email@example.com / +33 1 42 86 82 41
Read the press release (pdf): QUANTIFICARE – LBO France Press Release
Links toward the press:
Le Journal des entreprises, September 4th 2019 : Spécialiste de l’imagerie médicale 3D, QuantifiCare lève 5 M€ (pdf)
Silicon Canals, September 5th 2019: France-based clinical imaging scaleup Quantificare raises €5M in Series A funding (pdf)
Tribune Bulletin Côte d’Azur, September 5th 2019: La sophipolitaine QuantifiCare lève 5 M€ pour accélérer son expansion mondiale (pdf)
Les Echos, September 11th 2019: Quantificare veut devenir le leader de l’imagerie cutanée 3D (pdf)
French Web, September 11th 2019: Quantificare lève 5 millions d’euros pour développer l’imagerie médicale en 3D (pdf)
INRIA, September 11th 2019: QuantifiCare spin-off d’Inria renforce sa position de leader de l’imagerie médicale de la peau (pdf)
Biotech Finances, September 11th 2019: Quantificare boucle sa première levée de fonds à 5M€ auprès de LBO France, via son fonds Digital Health 2. (pdf)
Nice Matin, September 12th 2019: Leader mondial de l’imagerie cutanée, une PME de Sophia Antipolis lève 5 millions d’euros (pdf)
WebTimeMedias Riviera, September 13th 2019: Sophia : Quantificare (imagerie médicale cutanée) lève 5 M€ (pdf)
CCI Nice Côte d’Azur, September 23th 2019: Leader mondial de l’imagerie médicale 2D/3D, QuantifiCare lève 5 M€ (pdf)